What are the advantages, disadvantages, and translational challenges of routine and candidate biomarkers in the diagnosis of acute myocardial infarction?
This review summarizes the current landscape, advantages, and translational challenges of established and emerging biomarkers for diagnosing acute myocardial infarction.
We evaluated the advantages and disadvantages of routine enzymatic and nonenzymatic biomarkers and the literature evidence of other candidate biomarkers in the diagnosis of AMI, and discuss challenges and constraints that limit translational use from bench to bedside.
Aydın et al. (2019) studied this question.